Abstract:
Noninfectious ocular inflammation, particularly uveitis, continues to be a leading
cause of visual impairment and blindness globally. Traditionally, the management of
these conditions has depended on corticosteroids and immunosuppressive
therapies. However, in cases of severe inflammatory ocular disease, it is crucial to
balance the benefit of vision preservation against the risk of potentially serious
treatment-related side effects, which are often significant and may lead to longterm complications.
Recently, novel therapeutic strategies have emerged, bringing renewed hope.
Advances in biologic therapies, small molecule inhibitors, and targeted
immunomodulators are transforming the management of uveitis. These innovative
treatments are designed to reduce inflammation with greater precision, minimize
systemic adverse effects, and enhance long-term outcomes.
In this presentation, we will explore the potential of these groundbreaking
therapies, including IL-6 inhibitors, JAK inhibitors, and other targeted treatments, in
shaping the future of patient care.
